^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD20 positive

    i
    Other names: CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
    Entrez ID:
    494216
    Related biomarkers:
    Expression
    Others
    1d
    68Ga-pentixafor PET/CT shows better diagnostic performance than 18F-FDG PET/CT in chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and review of literature. (PubMed, Front Oncol)
    Compared with 18F-FDG, 68Ga-pentixafor PET/CT detected more lesions with significantly higher tracer uptake. This case suggests that, for patients with CLL/SLL, 68Ga-pentixafor PET/CT demonstrates significantly superior performance in evaluating the tumor burden and delineating the disease extent compared with 18F-FDG PET/CT.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive
    4d
    Dual-trigger model of CD20 escape: NONO regulation and cryptic splicing induced by transcript overload in pediatric B-ALL. (PubMed, Front Immunol)
    Together, these findings are consistent with a model in which NONO expression and transcript-level dynamics of MS4A1 are associated with CD20 heterogeneity in pediatric B-ALL. These observations may contribute to understanding variability in CD20 expression and antigen availability in pediatric B-ALL.
    Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • MS4A1 (Membrane Spanning 4-Domains A1) • NONO (Non-POU Domain Containing Octamer Binding)
    |
    CD20 positive
    5d
    GAZAI: Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma (clinicaltrials.gov)
    P2, N=89, Completed, Heidelberg University | Active, not recruiting --> Completed
    Trial completion
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab)
    6d
    GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
    |
    CD20 positive • Chr t(11;14)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Jaypirca (pirtobrutinib)
    6d
    Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study (clinicaltrials.gov)
    P2, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • SP140 (SP140 Nuclear Body Protein) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Columvi (glofitamab-gxbm)
    7d
    Central nervous system post-transplant lymphoproliferative disorder relapse after pediatric liver transplantation: a case report and literature review. (PubMed, Transl Pediatr)
    Therefore, we upgraded the treatment plan to R-CHOP chemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), and achieved a complete remission (CR)...We observe that the combination of HD-MTX and intrathecal chemotherapy exhibits remarkable efficacy in managing post-transplant CNS-PTLD that is resistant to conventional R-CHOP chemotherapy. CAR-T therapy emerges as a potential option for patients suffering from relapsed or refractory CNS-PTLD.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • methotrexate IV
    9d
    EBV-Negative Post-Lung Transplant Lymphoma Diagnosed via Paracentesis: A Case Report and Literature Review. (PubMed, Case Rep Transplant)
    Mycophenolate mofetil was discontinued, and tacrolimus levels were maintained at 6-8 ng/mL...EBV-negative PTLD is rare and often fatal. Ascitic fluid cytology can facilitate early, minimally invasive diagnosis, warranting high clinical suspicion in transplant recipients with unexplained ascites.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • MME (Membrane Metalloendopeptidase)
    |
    CD20 positive
    13d
    Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma (clinicaltrials.gov)
    P1, N=7, Terminated, Conjupro Biotherapeutics, Inc. | Phase classification: P1/2 --> P1
    Phase classification • First-in-human
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    CD20 positive
    |
    JMT601
    13d
    HOVON 178 WM: Treatment of Waldenstroms macroglobulinemia with epcoritamab if the disease comes back during or after previous treatment (2025-522295-91-00)
    P1/2, N=28, Not yet recruiting, Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting | N=14 --> 28
    Enrollment change
    |
    CD20 positive
    |
    Epkinly (epcoritamab-bysp)
    14d
    DEB: Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL (clinicaltrials.gov)
    P3, N=423, Completed, Chipscreen Biosciences, Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
    14d
    A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL (clinicaltrials.gov)
    P1, N=36, Completed, Otsuka Pharmaceutical Co., Ltd. | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Jan 2026
    Trial completion • Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • bendamustine • OPB-111077
    16d
    A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping (clinicaltrials.gov)
    P3, N=156, Not yet recruiting, Ruijin Hospital
    New P3 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    doxorubicin hydrochloride • cyclophosphamide